Patient advocacy organizations, industry funding, and conflicts of interest

JAMA Internal Medicine

Volumn 177, Issue 3, 2017, Pages 344-350

  Rose, Susannah L ^a,b   Highland, Janelle ^c   Karafa, Matthew T ^a   Joffe, Steven ^d  

^a LERNER RESEARCH INSTITUTE   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFLICT OF INTEREST; FEMALE; FINANCIAL MANAGEMENT; FUNDING; HEALTH CARE INDUSTRY; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; LEADERSHIP; MALE; NON PROFIT ORGANIZATION; PATIENT ADVOCACY; PRIORITY JOURNAL; REVIEW; UNITED STATES; BIOTECHNOLOGY; DEVICES; DRUG INDUSTRY; ECONOMICS; ETHICS; HEALTH CARE FINANCING; MANAGEMENT; PUBLIC HEALTH SERVICE;

BIOTECHNOLOGY; CONFLICT OF INTEREST; DRUG INDUSTRY; EQUIPMENT AND SUPPLIES; FINANCIAL MANAGEMENT; HEALTHCARE FINANCING; HUMANS; PATIENT ADVOCACY; POLICY MAKING; PUBLIC HEALTH ADMINISTRATION; UNITED STATES;

EID: 85015288238     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2016.8443     Document Type: Review

References (32)

1. Koay PP, Sharp RR. The role of patient advocacy organizations in shaping genomic science. Annu Rev Genomics Hum Genet. 2013;14:579-595.
2. Dresser R. When Science Offers Salvation: Patient Advocacy and Research Ethics. New York, NY: Oxford University Press; 2001.
3. Black D, Brockway-Lunardi L. The Melanoma Research Alliance: the power of patient advocacy to accelerate research and novel therapies. Cancer Immunol Res. 2013;1(6):357-361.
4. Cohen D, Raftery J. Paying twice: questions over high cost of cystic fibrosis drug developed with charitable funding. BMJ. 2014;348:1445-1448.
5. Smith SK, SeligW, Harker M, et al. Patient engagement practices in clinical research among patient groups, industry and academia in the United States: a survey. PLoS One. 2015;10(10): e0140232.
6. Baggott R, Jones K. The voluntary sector and health policy: the role of national level health consumer and patients' organisations in the UK. Soc Sci Med. 2014;123:202-209.
7. Hegde D, Sampat B. Can private money buy public science? disease group lobbying and federal funding for biomedical research. Manage Sci. 2015; 61(10):2281-2298. doi:10.1287/mnsc.2014.2107
8. Keller AC, Packel L. Going for the cure: patient interest groups and health advocacy in the United States. J Health Polit Policy Law. 2014;39(2):331-367.
9. Hughes D, Williams-Jones B. Coalition Priorité Cancer and the pharmaceutical industry in Quebec: conflicts of interest in the reimbursement of expensive cancer drugs? Healthc Policy. 2013;9(1): 52-64.
10. Herxheimer A. Relationships between the pharmaceutical industry and patients' organisations. BMJ. 2003;326(7400):1208-1210.
11. Jacobson MF. Lifting the veil of secrecy from industry funding of nonprofit health organizations. Int J Occup Environ Health. 2005;11(4):349-355.
12. Mintzes B. Should patient groups accept money from drug companies? no. BMJ. 2007;334(7600): 935.
13. Kent A. Should patient groups accept money from drug companies? yes. BMJ. 2007;334(7600): 934.
14. Quigley RB. Advocacy and Community: Conflicts of Interest in Public Health Research. Dordrecht, the Netherlands: Springer; 2004:223-235.
15. Harris G. Drug makers are advocacy group's biggest donors. New York Times. Oct 22, 2009. http://www.nytimes.com/2009/10/22/health/22nami.html?-r=0. Accessed May 2, 2016.
16. Lo B, Field MJ, eds. Conflict of Interest in Medical Research, Education, and Practice: Committee on Conflict of Interest in Medical Research, Education, and Practice: Institute of Medicine.Washington, DC: National Academies Press; 2009.
17. DeJong C, Aguilar T, Tseng CW, Lin GA, BoscardinWJ, Dudley RA. Pharmaceutical industry-sponsored meals and physician prescribing patterns for Medicare beneficiaries. JAMA Intern Med. 2016;176(8):1114-10.
18. Ball DE, Tisocki K, Herxheimer A. Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey. BMC Public Health. 2006;6:201-213.
19. Rothman SM, Raveis VH, Friedman A, Rothman DJ. Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices. Am J Public Health. 2011;101(4):602-609.
20. Colombo C, Mosconi P, VillaniW, Garattini S. Patient organizations' funding from pharmaceutical companies: is disclosure clear, complete and accessible to the public? an Italian survey. PLoS One. 2012;7(5):e34974.
21. Rose SL. Patient advocacy organizations: institutional conflicts of interest, trust, and trustworthiness. J Law Med Ethics. 2013;41(3):680-687.
22. Armstrong EM, Carpenter DP, Hojnacki M. Whose deaths matter? mortality, advocacy, and attention to disease in the mass media. J Health Polit Policy Law. 2006;31(4):729-772.
23. Gale Research. Encyclopedia of associations: national organizations of the US. http://find.galegroup.com/gdl/help/GDLeDirEAHelp.html. Accessed April 30, 2016.
24. NORD. National Organization for Rare Disorders. https://rarediseases.org. Accessed April 30, 2016.
25. United States Department of Health and Human Services. Subordinate organizations. http://www.directory.psc.gov/. Revised May 5, 2009. Accessed April 30, 2016.
26. GuideStar. https://www.guidestar.org/Home.aspx. Accessed April 30, 2016.
27. Lexis Nexis. http://www.lexisnexis.com/en-us/gateway.page. Accessed April 30, 2016.
28. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42(2):377-381.
29. SantoraM. In diabetes fight, raising cash and keeping trust. New York Times. November 26, 2006. http://www.nytimes.com/2006/11/25/health/25ada.html?pagewanted=all. Accessed May 2, 2016.
30. Ornstein C,Weber T. Patient advocacy group funded by success of painkiller drug, probe finds. Washington Post. December 23, 2011. https://www.washingtonpost.com/national/health-science/patient-advocacy-group-funded-by-success-of-painkiller-drugs-probe-finds/2011/12/20/gIQAgvczDP-story.html. Accessed May 2, 2016.
31. Centers for Medicare & Medicaid Services. Open Payments. https://www.cms.gov/openpayments/. Accessed October 12, 2016.
32. Robertson CT.Why blinding? how blinding? a theory of blinding and its application to institutional corruption. In: Robertson CT, Kesselheim AS, eds. Blinding as a Solution to Bias. London, United Kingdom: Academic Press; 2016.